Omnicell (OMCL) Expected to Announce Earnings on Thursday

Omnicell (NASDAQ:OMCL) is projected to issue its Q4 2025 results before the market opens on Thursday, February 5th. Analysts expect the company to announce earnings of $0.47 per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 5, 2026 at 8:30 AM ET.

Omnicell Price Performance

Shares of Omnicell stock opened at $49.04 on Thursday. The company has a current ratio of 1.44, a quick ratio of 1.21 and a debt-to-equity ratio of 0.14. Omnicell has a 12 month low of $22.66 and a 12 month high of $55.00. The stock has a 50 day moving average of $44.98 and a 200 day moving average of $36.20. The firm has a market cap of $2.20 billion, a PE ratio of 114.05, a PEG ratio of 5.32 and a beta of 0.77.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on OMCL. UBS Group set a $53.00 target price on Omnicell in a research note on Friday, January 16th. Weiss Ratings reissued a “sell (d+)” rating on shares of Omnicell in a research report on Thursday, January 22nd. KeyCorp raised shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price objective on the stock in a report on Wednesday, January 7th. Wells Fargo & Company lifted their price objective on shares of Omnicell from $43.00 to $52.00 and gave the company an “overweight” rating in a report on Monday, January 5th. Finally, Zacks Research downgraded shares of Omnicell from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 9th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Omnicell has a consensus rating of “Hold” and an average price target of $48.57.

Insider Buying and Selling

In other news, EVP Corey J. Manley sold 6,106 shares of Omnicell stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $49.90, for a total transaction of $304,689.40. Following the sale, the executive vice president owned 91,674 shares in the company, valued at approximately $4,574,532.60. The trade was a 6.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 2.52% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. CIBC Bancorp USA Inc. acquired a new stake in Omnicell in the 3rd quarter valued at about $224,000. Jacobs Levy Equity Management Inc. purchased a new position in Omnicell in the third quarter valued at approximately $1,924,000. Dark Forest Capital Management LP acquired a new stake in shares of Omnicell in the third quarter valued at about $438,000. Nomura Holdings Inc. increased its position in shares of Omnicell by 19.8% during the third quarter. Nomura Holdings Inc. now owns 99,690 shares of the company’s stock worth $3,036,000 after acquiring an additional 16,455 shares during the last quarter. Finally, Mariner LLC bought a new position in Omnicell during the 3rd quarter worth approximately $388,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.